Please check your internet connection and try again.
# Tradjenta (linagliptin)
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing incretin levels, which leads to a decrease in glucagon levels and an increase in insulin secretion in a glucose-dependent manner.
## Primary Indications
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antihyperglycemic agents, including metformin, sulfonylureas, and insulin.
## Adult Dosing
The recommended dose is 5 mg orally once daily.
## Pediatric Dosing
Dosing for pediatric patients has not been established.
## Dose Adjustments
No dose adjustment is required for patients with renal or hepatic impairment.
## Contraindications
* Known hypersensitivity to linagliptin or any excipients in the formulation.
* History of angioedema with DPP-4 inhibitors.
## Adverse Effects
Common adverse effects include nasopharyngitis and diarrhea. Rare but serious adverse effects include:
* Acute Pancreatitis: Symptoms include severe, persistent abdominal pain, which may radiate to the back with or without vomiting.
* Hypersensitivity Reactions: Including rash, urticaria, and angioedema.
* Severe and Disabling Arthralgia (joint pain).
* Hypoglycemia: Risk is increased when used in combination with sulfonylureas or insulin.
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., rifampin):** May decrease linagliptin exposure and efficacy. Concomitant use is not recommended.
* **Sulfonylureas/Insulin:** Increased risk of hypoglycemia. Consider a lower dose of sulfonylurea or insulin.
## Monitoring
* HbA1c: Monitor periodically to assess glycemic control.
* Renal function: While no dose adjustment is needed, monitor as clinically indicated.
* Signs and symptoms of pancreatitis and hypersensitivity reactions.
## Clinical Pearls
* Linagliptin is primarily eliminated unchanged by the liver and does not require dose adjustment in renal impairment, making it a convenient option for patients with varying degrees of kidney function.
* Patients should be educated on the signs and symptoms of pancreatitis and advised to seek medical attention if they occur.
* Advise patients to report any signs of angioedema immediately.
***
*Disclaimer: This information is intended for clinical pharmacists and healthcare professionals. It is crucial to consult the most current prescribing information and product labeling for complete details and to verify dosing and safety information before making any clinical decisions.*
